Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/ll Clinical Study of Safety and Efficacy of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

NCT06947226 is registered in ClinicalTrials.gov with Mabwell (Shanghai) Bioscience Co., Ltd. as lead sponsor.

NCT NCT06947226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06947226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/ll Clinical Study of Safety and Efficacy of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
Lead sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
April 30, 2025
Completion date
April 30, 2027
Enrollment
188 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors